Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol ATI001-102 Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Combination With Nivolumab in Subjects With Recurrent or Progressive Glioblastoma

NCT03636477 is registered in ClinicalTrials.gov with Alaunos Therapeutics as lead sponsor.

NCT NCT03636477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03636477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol ATI001-102 Substudy: Evaluation of Ad-RTS-hIL-12 + Veledimex in Combination With Nivolumab in Subjects With Recurrent or Progressive Glioblastoma
Lead sponsor
Alaunos Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
June 18, 2018
Completion date
June 30, 2021
Enrollment
21 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma